Connect with us

Health

COVID-19 Testing Stocks Move Lower After Abbott Receives EUA For 15-Minute Test – Benzinga

Abbott Laboratories (NYSE: ABT) announced late Wednesday the receipt of emergency use authorization from the FDA for its $5, 15-minute COVID-19 antigen …

Published

on

post featured image

Abbott Laboratories (NYSE: ABT) announced late Wednesday the receipt of emergency use authorization from the FDA for its $5, 15-minute COVID-19 antigen test.
Abbott’s BinaxNOW could be transformative, Morgan Stanley analyst David Lewis said in a note.
The test is bigger and better than expected, given the $5 price point; the fact that it’s a nasal swab; its better-than-expected performance; and a higher shipment volume, the analyst said. 
The Sympathy Move: The announcement, though catalyzing…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending